Dr. Silverberg explores best practices for counseling patients with atopic dermatitis when weighing treatment options, particularly the decision between topical and oral JAK inhibitors. His discussion focuses on individualized risk–benefit assessment, shared decision-making, and ensuring patients clearly understand safety considerations and expected outcomes.
Topics Covered:
- Comparing topical versus oral JAK inhibitors in atopic dermatitis
- Reviewing safety profiles and monitoring considerations
- Communicating risks, benefits, and expectations effectively
- Incorporating patient preferences into treatment selection
Explore Related Resources:
